Clinical Trials Browser

Phase 2/3 × Docetaxel × 1 year × Clear all

NCT05063552 2026-03-18

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT01810913 2026-03-13

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Phase 2/3 Recruiting

613 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT07459751 2026-03-10

A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Phase 2/3 Not yet recruiting

671 enrolled

Thoracic

Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

NCT03070886 2026-01-14

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

Phase 2/3 Completed

612 enrolled

Genitourinary

Stage I Prostate Adenocarcinoma AJCC v7

NCT03258320 2026-01-12

A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients

Phase 2/3 Recruiting

300 enrolled

Genitourinary

Prostatic Neoplasms

NCT05096663 2025-05-15

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Phase 2/3 Active not recruiting

82 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06028737 2025-05-06

OCTASUR

Phase 2/3 Recruiting

150 enrolled

Gastrointestinal

Gastrointestinal Neoplasms, Neoplasms, Stomach Neoplasms

NCT01779206 2025-04-08

ADAPT

Phase 2/3 Completed

4,936 enrolled

Breast

Breast Neoplasms